Cargando…

Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study

OBJECTIVE: To evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of iberdomide in patients with SLE. Iberdomide is a high-affinity cereblon ligand that targets the hematopoietic transcription factors Ikaros and Aiolos for proteasomal degradation. METHODS: A 12-week, multicentre, double...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furie, Richard A, Hough, Douglas R, Gaudy, Allison, Ye, Ying, Korish, Shimon, Delev, Nikolay, Weiswasser, Michael, Zhan, Xiaojiang, Schafer, Peter H, Werth, Victoria P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immunology and Inflammation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852715/ https://www.ncbi.nlm.nih.gov/pubmed/35169036 http://dx.doi.org/10.1136/lupus-2021-000581

Ejemplares similares

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator
por: Ye, Ying, et al.
Publicado: (2020)

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus
por: Schafer, Peter H, et al.
Publicado: (2018)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Intermuscular adipose tissue in patients with systemic lupus erythematosus
por: Gamboa, Jorge Luis, et al.
Publicado: (2022)

Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus
por: Rivellese, Felice, et al.
Publicado: (2021)

Brain MRI in patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus
por: Arinuma, Yoshiyuki, et al.
Publicado: (2014)

Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus
por: Han, Bobby Kwanghoon, et al.
Publicado: (2020)

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Morand, Eric, et al.
Publicado: (2022)

Reduced response to Epstein–Barr virus antigens by T-cells in systemic lupus erythematosus patients
por: Draborg, Anette Holck, et al.
Publicado: (2014)

Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis
por: Xiang, Shate, et al.
Publicado: (2022)

Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus
por: Hanly, John G, et al.
Publicado: (2022)

Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus
por: Fasano, Serena, et al.
Publicado: (2023)

High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus
por: Maeda, Shinji, et al.
Publicado: (2023)

Increased alloreactive and autoreactive antihuman leucocyte antigen antibodies associated with systemic lupus erythematosus and rheumatoid arthritis
por: Jackman, Rachael P, et al.
Publicado: (2018)

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
por: Neupane, Binod, et al.
Publicado: (2023)

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
por: Khamashta, Munther, et al.
Publicado: (2016)

Ultrasound detects subclinical joint inflammation in the hands and wrists of patients with systemic lupus erythematosus without musculoskeletal symptoms
por: Ruano, Carina A, et al.
Publicado: (2017)

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
por: Cheng, Yiming, et al.
Publicado: (2023)

Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation
por: Nossent, Johannes C, et al.
Publicado: (2016)

Combining C reactive protein and serum albumin to predict 90-day mortality in systemic lupus erythematosus with serious community-acquired infections
por: He, Shuangjun, et al.
Publicado: (2021)

Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre
por: Hill, Deanna D, et al.
Publicado: (2021)

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme
por: Maslen, Toni, et al.
Publicado: (2021)

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept
por: Tarazi, Meera, et al.
Publicado: (2018)

Alopecias in lupus erythematosus
por: Concha, Josef Symon Salgado, et al.
Publicado: (2018)

Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2020)

Pathophysiology of cutaneous lupus erythematosus
por: Achtman, Jordan C, et al.
Publicado: (2015)

Subacute cutaneous lupus erythematosus versus discoid lupus erythematosus: A challenging diagnosis
por: Kleitsch, Julianne, et al.
Publicado: (2023)

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2021)

Ascending Reproductive Tract Infection in Pig-Tailed Macaques Inoculated with Mycoplasma genitalium
por: Aguila, Laarni Kendra T., et al.
Publicado: (2022)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus
por: Chen, Kristen L., et al.
Publicado: (2019)

Lupus serum induces inflammatory interaction with neutrophils in human glomerular endothelial cells
por: Russell, Dayvia A, et al.
Publicado: (2020)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
por: Werth, Victoria P, et al.
Publicado: (2021)

A novel monocyte differentiation pattern in pristane-induced lupus with diffuse alveolar hemorrhage
por: Han, Shuhong, et al.
Publicado: (2022)

Emerging Therapies in Cutaneous Lupus Erythematosus
por: Sprow, Grant, et al.
Publicado: (2022)

Bullous systemic lupus erythematosus in females
por: Sprow, Grant, et al.
Publicado: (2022)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
por: Furie, Richard A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ht0fvjo0b1t2qrs9pil2bmta9e